<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Decreased plasma level of antithrombin III was assumed to be one of the major factors underlying <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> in <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Concentrated antithrombin III preparation was given to 8 children with <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> with a plasma antithrombin III activity of less than 70%, to evaluate the effect on <z:e sem="disease" ids="C0398623" disease_type="Disease or Syndrome" abbrv="">hypercoagulable state</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Plasma antithrombin III activity was elevated to more than 70% in 7 of 8 children after treatment, while plasma levels of plasmin-alpha 2 plasmin inhibitor complex and FDP-D dimer were not significantly decreased </plain></SENT>
<SENT sid="3" pm="."><plain>One patient developed <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> after the treatment, suggesting that prophylactic administration of concentrated antithrombin III preparation is not fully protective against thrombotic complications in <z:hpo ids='HP_0000100'>nephrotic syndrome</z:hpo> </plain></SENT>
</text></document>